ERBB2 and cancer: In the entire cohort, HER2‐low cancers showed lower rates of grade 3 (25.4% vs. 33.6%, p < 0.001) and bone metastasis (8.1% vs. 9.8%, p = 0.013, ‘metastasis’ here means those emerging during follow‐up).